Exelixis | EXEL - Capitaux Propres Et Réserves

Prix De L'Action
44.94
Variation Quotidienne
-1.11 -2.41%
Mensuellement
5.04%
Annuel
20.06%
Q2 Prévisions
43.98




Capitaux Propres Et Réserves Changement Date
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Akebia Therapeutics USD 32.61M 8.98M 2025-12
Amgen USD 8.66B 961M 2025-12
AstraZeneca USD 48.67B 2.78B 2025-12
Bayer EUR 25.95B 3.75B 2025-12
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Cytokinetics USD -659.62M 138.5M 2025-12
Eisai JPY 889.64B 35.21B 2025-12
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Exelixis USD 2.16B 619K 2025-12
Genmab DKK 5.85B 96M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.17B 516.28M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
MacroGenics USD 55.59M 11.41M 2025-12
Merck USD 51.85B 2.79B 2025-09
Moderna USD 8.65B 680M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sanofi EUR 71.71B 14.25B 2025-12
Takeda JPY 7.64T 513.39B 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Xencor USD 635.59M 10.27M 2025-12